The Food and Drug Administration recently approved two novel thrombopoiesis-stimulating agents, Romiplostim (AMG-531, Nplate) and Eltrombopag (Promacta), for the treatment of adults with immune thrombocytopenic purpura. For physicians taking care of critically ill neonates, this offers the opportunity of decreasing platelet transfusions and potentially improving the outcomes of neonates with severe and prolonged thrombocytopenia. However, several developmental factors need to be taken into consideration. First, the population of thrombocytopenic neonates likely to benefit from these agents needs to be carefully selected. Second, the mechanisms underlying neonatal and adult thrombocytopenia differ from each other and are incompletely understood, and pre-clinical evidence suggests that the response of neonates to thrombopoietic factors might be different from that of adults. Finally, the potential non-hematopoietic effects of thrombopoietin have not been well established. Here, we will discuss these issues in detail, and will highlight the critical developmental differences between neonates and adults that need to be considered as we think about introducing these agents into neonatal care.
Introduction
Neonatal cytopenias (anemia, thrombocytopenia, and neutropenia) are common problems among infants admitted to the neonatal intensive care unit (NICU). [1] [2] [3] If treatment is required, cytopenias can be corrected by either transfusing the cells that are deficient, or by stimulating the endogenous production of the affected cell line with the use of specific growth factors. Historically, the availability of recombinant erythropoietin (Epo) and granulocyte colonystimulating factor prompted a flurry of studies using these agents in neonates with anemia or neutropenia, respectively. In fact, although not as widespread as before, Epo is still used to treat anemia of prematurity 4 and granulocyte colony-stimulating factor continues to be used in neonates with severe neutropenia of different etiologies. 5 In contrast to Epo and granulocyte colony-stimulating factor, the most potent stimulator of platelet production was not identified until 1994, when thrombopoietin (Tpo) was clonedFalmost simultaneouslyFby five independent groups around the world. The importance of this discovery was evidenced by the speed with which the new molecule moved from bench to clinical studies. These centered around two recombinant forms of Tpo: a full-length Tpo (rhTpo) and a pegylated form containing only the receptorbinding domain, named pegylated recombinant human megakaryocyte-growth-and-development factor (PEG-rHuMGDF). When Food and Drug Administration approval of these compounds seemed imminent, however, a number of subjects treated with PEG-rHuMGDF developed cross-reactive neutralizing antibodies against their endogenous Tpo, which led to severe hyporegenerative thrombocytopenia and aplastic anemia. 6, 7 The seriousness of this side effect eventually caused the discontinuation of all clinical development efforts for Tpo. Clinical trials evaluating the effect of rhTpo in thrombocytopenic neonates were, therefore, never carried out.
The termination of all studies involving rhTpo triggered an active search for so-called 'second generation' thrombopoietic factors. This culminated with the discovery of several 'Tpomimetics', molecules that do not share any sequence homology with endogenous Tpo, but stimulate thrombopoiesis by binding and activating the Tpo receptor. 8 This new family of agents includes Tpo-mimetic peptides (AMG-531 and Fab-59), Tpomimetic non-peptides (Eltrombopag, LGD-4665, AKR-501, and Butyzamide), and Tpo agonist antibodies (VB22B sc(Fv) 2 and MA01G4G344). 9 Among those, AMG-531 (Nplate, Romiplostim) and Eltrombopag (Promacta) were recently approved by the Food and Drug Administration for the treatment of adults with immune thrombocytopenic purpura refractory to conventional therapy. Initial clinical trials evaluating Eltrombopag and Romiplostim in adult patients consistently showed high efficacy and a favorable safety profile. 10, 11 However, all clinical studies so far have exclusively focused on adult patients with a naturally long disease course, and who were refractory to other established treatment protocols.
Significance of neonatal thrombocytopenia Thrombocytopenia, classically defined as a platelet count below <150 000 per ml, is a common problem among sick neonates. In fact, 20-35% of all neonates admitted to an NICU have at least one platelet count <150 000 per ml.
2 Extremely low birth weight infants (<1000 g birth weight) are even more likely to have thrombocytopenia, with approximately 70% of them developing this problem. 12 To this date, the only available treatment option for newborns with non-immune thrombocytopenia has been to administer platelet transfusions. Owing mostly to a lack of solid evidence to guide transfusion decisions in neonates, transfusion guidelines and practices differ substantially among centers and among individual neonatologists. 13 However, based on published single-institution studies, it has been estimated that approximately 32 000 (8%) of the 400 000 neonates admitted to NICUs in the USA each year receive at least one platelet transfusion. Approximately half of these infants receive two or more transfusions. 14 The incidence of transfusion-related complications in neonates is unknown. However, several studies in adults have shown that platelet transfusions, in particular, are associated with substantial risks, such as bacterial infection and transfusion-associated lung injury. Given the high incidence of sepsis and respiratory decompensation episodes among neonates, it is likely that these transfusion complications are under-recognized in the NICU setting. Furthermore, several studies have documented a direct correlation between the number of platelet transfusions and morbidity and mortality in neonates. It is unclear whether this simply reflects the fact that sicker patients receive more platelet transfusions, but at least one study has suggested that platelet transfusions per se might contribute to the high mortality. 15 Given these facts, pharmacologically stimulating platelet production and decreasing the need for platelet transfusions in infants with prolonged and severe thrombocytopenia might lead to improved outcomes among such neonates.
Use of thrombopoietic agents in neonates: special considerations Platelet formation is a complex process. The first step is the production of a thrombopoietic stimulus, which promotes the commitment of hematopoietic stem cells toward megakaryocytic differentiation and the proliferation of megakaryocyte progenitors (the cells that multiply and give rise to megakaryocytes). Immature megakaryocytes then undergo a maturational process, consisting of a progressive increase in nuclear ploidy and cytoplasmic maturation that ultimately generates large polyploid cells capable of releasing platelets into the circulation. 16 From a pathophysiological perspective, our understanding of the mechanisms underlying low platelet counts in neonates is still limited. We know, however, that there are important developmental differences between neonatal and adult megakaryocytes, which likely contribute to the vulnerability of neonates to develop prolonged and severe thrombocytopenia. Among these differences, neonatal megakaryocytes are significantly smaller and of lower ploidy than adult megakaryocytes, 17, 18 and smaller megakaryocytes are known to give rise to less platelets. 19 Under normal conditions, this apparent impairment is circumvented by the higher proliferative potential of neonatal megakaryocyte progenitors, 20, 21 which generate megakaryocytes faster and in higher numbers than adult progenitors. During thrombocytopenia, however, recent studies have suggested that neonates might not be able to upregulate platelet production to the degree that adults do. Specifically, adults with consumptive thrombocytopenia can increase platelet production by two-to eightfold, and they do so by increasing the size and number of their marrow megakaryocytes. 22, 23 Neonates, in contrast, seem to have a limited ability to increase the size of their megakaryocytes, thus abrogating one of the compensatory mechanisms of adults. 24, 25 Furthermore, neonates with certain varieties of thrombocytopenia have lower Tpo levels than adults with similar mechanisms of thrombocytopenia. 20, 26 Taken together, these findings imply a generally lower potential of neonates to increase thrombopoiesis in response to increased platelet demand, and provide a good rationale to consider the use of thrombopoiesis-stimulating agents in this population.
However, a number of developmental factors need to be taken into consideration when deciding how to introduce these agents in neonatal care. First, it will be critical to carefully determine which neonates would benefit from treatment with thrombopoiesisstimulating agents. In this regard, we know that Tpo and Tpo mimetics begin to increase the platelet count 4-6 days after the start of therapy, and reach peak platelet counts at 10-14 days. Thus, only infants whose disease process would predict a platelet transfusion requirement lasting longer than 2 weeks would be appropriate candidates for treatment. 27 Given that approximately 80% of cases of severe thrombocytopenia in the NICU resolve within 14 days, 28 this constitutes the minority of thrombocytopenic neonates. Furthermore, there are currently no markers that allow us to predict which neonates will experience prolonged thrombocytopenia, although two studies have shown an association between liver disease and prolonged thrombocytopenia in neonates.
As the liver is the main site of Tpo production in neonates and adults, 29 infants with liver failure and severe thrombocytopenia might be attractive potential candidates. 14, 30 Many infants with congenital viral infections might fall into this category. This approach has already been tested in adults with thrombocytopenia because of HCV-related cirrhosis, in whom treatment with Eltrombopag increased the platelet counts and permitted the initiation of antiviral therapy.
The neonates who receive the largest numbers of platelet transfusions ('very high users', >20 platelet transfusions), however, belong primarily to four groups: extracorporeal membrane oxygenation (ECMO), bacterial or fungal sepsis, necrotizing enterocolitis (NEC), or congenital hyporegenerative thrombocytopenias (such as thrombocytopenia with absent radii syndrome or congenital amegakaryocytic thrombocytopenia). 31 In the specific cases of ECMO, sepsis, and NEC, the predominant mechanism of the thrombocytopenia is increased platelet activation and consumption, although recent data suggest that neonates with sepsis or NEC can also have an insufficient compensatory increase in thrombopoiesis. 32 Thus, infants with these conditions might be particularly appealing candidates for treatment with Tpo mimetics. However, two important challenges need to be dealt with when considering this approach. First is the duration of thrombocytopenia in these disease processes. In the case of ECMO, a recent review of 22 032 neonatal runs reported a median duration of ECMO of 5.4 days (mean±s.d. of 6.4±3.7 days), 33 implying that therapy with Tpo mimetics would not benefit the majority of neonates on ECMO. Similarly, the thrombocytopenia associated with sepsis and NEC resolves within 1-2 weeks in the majority of adequately treated neonates, although in someFfor unexplained and unpredictable reasonsFthe thrombocytopenia persists for several weeks. In this regard, the newly developed 'immature platelet fraction' (a measure of new platelet production) might become a helpful parameter to predict the duration of thrombocytopenia in neonates. 34 A second consideration is the fact that ECMO, sepsis, and NEC are associated with high levels of platelet activation. In vitro studies have shown that Tpo and Romiplostim (but not Eltrombopag) 35 increase the degree of platelet activation in response to agonists. Thus, the potential of Tpo-mimetic agents to increase the risk of thrombosis needs to be considered, particularly during the acute phase of clinical conditions already characterized by high levels of platelet activation.
In regard to congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii, their pathogenesis involves mutations in the Tpo receptor and defective intracellular Tpo signaling, respectively, which renders these diseases naturally unresponsive to Tpo. For that reason, Tpo mimetics are currently not indicated for these conditions, although it is possible that patients with specific mutations in the Tpo receptor might respond to certain receptor agonists. 36 From a biological perspective, it will also be essential to carefully evaluate the effects of Tpo and its mimetics specifically on neonatal megakaryocytopoiesis. We know so far that neonatal megakaryocyte progenitors are more sensitive to Tpo in vitro, and respond to lower Tpo concentrations than adult megakaryocyte progenitors. 37 In concordance with these in vitro findings, newborn rhesus monkeys treated with PEG-rHuMGDF achieved maximal platelet counts at lower doses than those needed to treat adult animals. 38 Qualitative differences in the response to Tpo between neonatal and adult megakaryocytes have also been reported. Specifically, Tpo has been shown to potently stimulate the nuclear maturation of adult megakaryocytes, whereas inhibiting the same process in neonatal megakaryocytes. 39 The molecular mechanisms underlying these findings are unknown, but it is evident that there are substantial molecular differences between neonatal and adult megakaryocytes.
Taken together, the available data suggest that Tpo mimetics will stimulate platelet production in neonates, but may do so through different mechanisms and at different doses (per kg) than in adults. Furthermore, all hematopoietic cytokines have been shown to affect cells and tissues outside the hematopoietic system. Epo, for example, has antiapoptotic properties on several cell types, including neuronal, myocardial, and hepatic cells. 40 Other nonhematopoietic effects of Epo include its pro-angiogenic effect on vascular cells, which might contribute to the higher incidence of retinopathy of prematurity among anemic infants treated with Epo during the first week of life. 41 The non-hematopoietic effects of Tpo have not yet been well characterized, particularly in a developing organism. However, it is known that Tpo and its receptor are expressed in the brain, 42 and recent data suggest that Tpo might have pro-apoptotic and differentiation-blocking effects on neuronal cells. 43, 44 This might be particularly important as Romiplostim and Eltrombopag have lower molecular weights than Tpo, and might be more likely to cross the blood-brain barrier. Given these considerations, a careful evaluation of potential non-hematopoietic effects on the developing organism is warranted.
Conclusion
The recent availability of novel thrombopoiesis-stimulating agents with a favorable safety profile in adults has opened the door to a new and promising therapeutic approach for severe neonatal thrombocytopenia. However, neonatologists and hematologists need to be aware of developmental factors that affect the decision of when and how to use these agents in neonates. First, the group(s) of neonates that will likely benefit from this treatment need to be carefully defined. Second, the pharmacokinetic and pharmacodynamic properties of these agents in neonates need to be determined. Noteworthy is the earlier experience with Epo in the treatment of anemia of prematurity, which revealed substantial pharmacokinetic differences between neonates and adults. 45 Third, Novel thrombopoietic agents H Sallmon et al the differences between neonatal and adult megakaryocytes in their responses to thrombopoietic agents need to be better characterized. And fourth, the potential non-hematopoietic effects of these novel factors should be carefully considered, particularly when used in a developing organism.
In conclusion, we believe that Tpo mimetics bring the promise of reducing platelet transfusions and potentially improving the outcomes of neonates with prolonged and severe thrombocytopenia. However, we also believe that a non-judicious extrapolation of results from adult studies to neonates could represent a significant pitfall. Thus, it is our opinion that further preclinical studies evaluating these issues are warranted, and that these novel thrombopoietic agents should currently be used in neonates only within the context of clinical trials designed to address the questions posed above, and that take into account the profound differences between neonatal and adult patients.
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